ELEDON PHARMACEUTICALS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36620 (Exact Name of Registrant as Specified in its Charter) Delaware 20-1000967 (State or other jur ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-42400 WILLOW LANE ACQUISITION CORP. (MARK ONE) | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | --- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39927 SEASTAR MEDICAL HOLDING CORPORATION (Exact name of Registrant as specified in its Charter) Delaware 85-3681132 (State or o ...

EXHIBIT 99.1 NEWS RELEASE CONTANGO ORE, INC. Facilities ("DOT"). The lawsuit related to trucking ore from Manh Choh to Fort Knox. We are pleased with dismissal of the lawsuit and its potential favorable impacts for the Manh Choh project and for trucking related to mining projects in general. On May 6, 2025, we announced the completion of a Technical Report Summary ("TRS") on the Johnson Tract Project, which summarized the results of an Initial Assessment ("IA") of the potential viability for a seven-year LO ...

Financial Performance - Enveric reported a net loss of $2,184,966 for the three months ended March 31, 2025, compared to a net loss of $2,456,915 for the same period in 2024, reflecting a decrease of approximately 11%[88]. - Total operating expenses decreased to $2,187,533 for Q1 2025, down from $2,477,317 in Q1 2024, a reduction of about 12%[88]. - General and administrative expenses fell by $525,615, or 28%, to $1,360,138 in Q1 2025, primarily due to reductions in various operational costs[90]. - Research and development expenses increased by $240,216, or approximately 47%, to $746,371 in Q1 2025, driven by higher consulting fees[91]. - The accumulated deficit reached $108,259,471 as of March 31, 2025, with ongoing losses anticipated in the company's development efforts[93]. - The company reported a net cash used in operating activities of $2,391,582 for the three months ended March 31, 2025, compared to $2,598,347 for the same period in 2024, reflecting a decrease of approximately 8%[98][99]. - The company experienced a net increase in cash of $2,053,409 for the three months ended March 31, 2025, compared to $4,068,059 in 2024, indicating a decrease of approximately 49%[97]. Cash Position and Financing - Enveric has cash of $4,294,435 and working capital of $3,650,434 as of March 31, 2025, which is insufficient to meet operating cash needs for the next 12 months[94]. - The company plans to raise additional working capital through public or private equity or debt financings, including an "at-the-market" offering of up to $1.8 million[94]. - Net cash provided by financing activities was $4,448,914 for the three months ended March 31, 2025, down from $6,658,269 in 2024, representing a decline of about 33%[100][101]. Development and Research - Enveric's lead drug candidate, EB-003, is currently in preclinical development with an IND filing expected as the next step[84]. - The company has synthesized over one thousand molecules from its Psybrary™, which includes 20 patent families covering a million potential molecular structures[80]. - Enveric out-licensed the EVM201 Series program to MycoMedica Life Sciences, which will seek to develop and commercialize EB-002, in exchange for development and milestone payments[79]. Going Concern and Risks - The company has substantial doubt about its ability to continue as a going concern for one year after the date of the financial statements[95]. - The company's critical accounting estimates involve significant uncertainty, particularly regarding accruals associated with third-party providers supporting research and development efforts[102]. - The company's primary market risk exposure is related to foreign currency exchange rates, particularly with the Canadian dollar and Australian dollar against the U.S. dollar[105]. - The company has not entered into any financial derivative instruments to hedge against foreign currency exchange rate risks, but may consider such hedging in the future[106]. - The net cash used in operating activities for the three months ended March 31, 2025, included a net loss adjusted for non-cash items of $1,912,659[98]. - The company has not reported any material changes to its critical accounting estimates compared to the previous year[103].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________. Commission file number: 0-21121 TRANSACT TECHNOLOGIES INC (Exact name of registrant as specified in its charter) | Delawa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___________ to __________ Commission file number: 001-34643 AYRO, INC. (Exact name of registrant as specified in its charter) | Delaware | 98-0204758 | | --- | ...

Revenue and Profitability - Revenue for the three months ended March 31, 2025, was $629,000, representing a 146% increase from $255,000 in the same period of 2024[12] - For the three months ended March 31, 2025, total net revenue was $629,000, a 147.1% increase from $255,000 in the same period of 2024[56] - Revenue from Components was $492,000, significantly up from $159,000 in the prior year, while Consumer Audio Products revenue increased to $137,000 from $96,000[56] - Gross profit for Q1 2025 was $69,000, compared to a gross deficit of $83,000 in Q1 2024[13] - The cost of net revenue for the same period was $560,000, compared to $338,000 in 2024, resulting in a gross loss of $9,563,000 for Q1 2025, compared to a net income of $2,707,000 in Q1 2024[170] Expenses and Losses - Total operating expenses increased to $9,500,000 in Q1 2025, up 133% from $4,075,000 in Q1 2024[13] - The net loss attributable to common stockholders for Q1 2025 was $9,563,000, compared to a net loss of $3,135,000 in Q1 2024[13] - Net cash used in operating activities was $6,024,000 for Q1 2025, an increase from $3,540,000 in Q1 2024, indicating higher cash outflows[21] - The company incurred salaries, benefits, and stock-based compensation expenses of $3,558,000 for Q1 2025, up from $2,284,000 in Q1 2024, indicating a 56% increase[170] - Research and development expenses increased to $2,361,000 in Q1 2025, up $646,000 from $1,715,000 in Q1 2024, primarily due to increased headcount and related costs[204] - Sales and marketing expenses rose to $1,495,000 in Q1 2025, an increase of $566,000 from $929,000 in Q1 2024, mainly due to higher salaries and consulting expenses[205] - General and administrative expenses surged to $5,644,000 in Q1 2025, an increase of $4,213,000 from $1,431,000 in Q1 2024, largely due to increased amortization and headcount-related costs[206] Cash and Liquidity - Cash and cash equivalents decreased to $171,000 as of March 31, 2025, down from $3,330,000 as of December 31, 2024[9] - The company had cash and cash equivalents of $171,000 at the end of Q1 2025, down from $2,763,000 at the end of Q1 2024, reflecting a decrease in liquidity[21] - Total current assets decreased to $2,693,000 as of March 31, 2025, from $6,439,000 as of December 31, 2024[9] Compliance and Regulatory Issues - The company has received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, with a compliance period until November 3, 2025, to regain compliance[27] - The company has been granted a 180-day grace period to regain compliance with the minimum bid price requirement, which is critical for maintaining its Nasdaq listing[28] Stock and Equity - The company issued 5,986,893 common shares as stock-based compensation during the three months ended March 31, 2025[16] - The weighted average number of common shares used in computing net loss per common share was 53,681,828 for Q1 2025[13] - The company executed a 1-for-150 reverse stock split in April 2024, which has been retroactively adjusted in the financial statements[30] - The company issued common stock purchase warrants in connection with the February 2024 Public Offering, with a fair value of $6.308 million allocated to the warrants liability[126] Liabilities and Debt - Total liabilities decreased to $13,987,000 as of March 31, 2025, from $14,899,000 as of December 31, 2024[9] - The company issued promissory notes totaling $1,000,000 on January 19, 2024, with gross proceeds of $600,000 received before fees and expenses[97] - The DV Convertible Note was issued with a principal amount of $10,000,000, maturing on December 31, 2027, and carries an interest rate of 5.12% per annum[102] - As of March 31, 2025, the carrying value of the DV Convertible Note was $9,582,000 after a partial repayment of $406,000[108] Inventory and Assets - Total inventories decreased from $1.618 million on December 31, 2024, to $1.342 million on March 31, 2025[87] - Property and equipment, net increased from $58,000 on December 31, 2024, to $98,000 on March 31, 2025[87] - The company has made a deposit of $2 million related to a pending acquisition of CompuSystems Inc, recorded as "deposit on business combination" as of March 31, 2025[95] Future Outlook and Risks - The Company expects operating losses to continue due to additional costs related to research and development, plans to expand its product portfolio, and increase market share[78] - The Company will need to raise additional funds in the next 12 months through selling equity or incurring debt, raising substantial doubt about its ability to continue as a going concern[79] - The company has incurred recurring losses since inception and is subject to risks associated with being an emerging business[201]

Exhibit 99.1 INNOVATIVE SOLUTIONS & SUPPORT REPORTS SECOND QUARTER 2025 RESULTS Exton, PA, May 14, 2025 – Innovative Solutions & Support, Inc. (Nasdaq: ISSC) ("IS&S" or the "Company"), a leading provider of advanced avionic solutions for commercial, business aviation and military markets, today reported fiscal second quarter financial results for the three-month period ended March 31, 2025. SECOND QUARTER 2025 HIGHLIGHTS (all comparisons versus the prior year period unless otherwise noted) MANAGEMENT COMMEN ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _____________________________________________________________ FORM 10-Q _____________________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-37756 _____________ ...